Page 1692 - Clinical Small Animal Internal Medicine

1630 Index

public health (cont’d) computed tomography pulmonary superficial pyodermas 1463–1465,
VetBooks.ir Wolbachia pipientis infection 918 definitive diagnostic imaging surface pyodermas 1461–1463,
angiography 319, 319
1463–1464
West Nile virus 900
yersiniosis 954
319–320
1462–1463
PUFA see polyunsaturated fatty acids diagnosis 314–320 systemic therapy 1468–1469
pulmonary edema etiology/pathophysiology 313, 314 topical therapy 1469
acute respiratory failure 382, heart failure 191–192 treatment 1468–1470
388–389 initial diagnostics 315–316, 316 pyogenic granuloma 536, 537
canine myocardial disease magnetic resonance imaging and pyogranulomatous disease 921, 922
254–255, 261 clot‐labeling techniques 319 pyothorax 337, 339–341, 340, 427
cardiogenic shock 416 management 320–323 pyrexia
feline myocardial disease 268 mechanical ventilation 393 feline inflammatory liver
gastrointestinal imaging 475 respiratory pattern‐based approach disease 688
heart failure 183 to dyspnea 293–294 gallbladder and extrahepatic biliary
mechanical ventilation 393 risk profiling 316–317, 317 ducts 722
pericardial disease 277 selective pulmonary angiography respiratory pattern‐based approach
pulmonary thromboembolism 313 319–320 to dyspnea 292
respiratory pattern‐based suggested diagnostic approach/ surgical approaches to thoracic
approach to dyspnea 289, algorithm 314–315, 315 disease 330
292–293 supportive therapy 320 pythiosis 999–1000
valvular heart disease 246 thrombolysis 320–321 diagnosis 1000
pulmonary function testing pulmonary valve stenosis (PS) 231, epidemiology and signalment 1000
307–308 233–235, 238, 241, 243–244 etiology/pathophysiology
pulmonary hypertension (PH) 138, pulmonary vascular resistance 999–1000
154, 225–230 (PVR) 227 history and clinical signs 1000
congenital heart disease pulse 405–406, 448 public health implications 1000
241–242 pulse oximetry 327 treatment and prognosis 1000
diagnosis 226–227 PU/PD see polyuria and polydipsia Pythium spp. 550
echocardiography 227, 228–229 pupillary light reflex (PLR) 823–824
electrocardiography 227, 228 pupils 736–737 q
epidemiology 225 purine urolithiasis 1128–1129, 1128 Q fever 959–961
etiology/pathophysiology 225, 226 pustules 1384, 1429 diagnosis 960
heart failure 193–194 PV see papillomaviruses; pemphigus epidemiology 959
history and clinical signs 226 vegetans; pemphigus vulgaris; etiology/pathophysiology 959
physical examination 226 polycythemia vera history and clinical signs 960
prognosis 229 P‐values 8–10, 25 prognosis 960
pulmonary thromboembolism 313, PVH‐MVD see portal venous public health implications 960
319–320 hypoplasia/microvascular signalment 960
right heart catheterization 227 dysplasia treatment 960
signalment 226 PVR see pulmonary vascular quality of life 1557–1561, 1557, 1558,
thoracic radiography 227, 227 resistance 1559–1561
treatment 228–229 pyelography 1093
pulmonary infarction 313, 316 pyloric obstruction 485, 485–486 r
pulmonary neoplasia 229 pyoderma 1461–1470 RAAS see renin‐angiotensin‐
pulmonary parenchyma 292–293, 293 classifications and presentations aldosterone system
pulmonary regurgitation 144, 147, 1461–1467 rabies 891–897
154–155 deep pyodermas 1465–1467, clinical signs 893–894
pulmonary thromboembolism 1465–1467 diagnosis 894
(PTE) 313–323 etiology/pathophysiology 1461 epidemiology 891–892
acute respiratory failure 386 methicillin‐resistant and etiology/pathophysiology 891
antithrombic strategies 321–323 multidrug‐resistant history 892–893
cardiac function testing staphylococci 1467–1468 preexposure/postexposure
318–319, 318 Staphylococcus aureus phage lysate prophylaxis 896–897
clinical signs 314 therapy 1470 prevention 892–897